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The three-dimensional structure of human procarboxy-
peptidase A2 has been determined using X-ray
crystallography at 1.8 Å resolution. This is the first
detailed structural report of a human pancreatic carb-
oxypeptidase and of its zymogen. Human procarboxy-
peptidase A2 is formed by a pro-segment of 96 residues,
which inhibits the enzyme, and a carboxypeptidase
moiety of 305 residues. The pro-enzyme maintains the
general fold when compared with other non-human
counterparts. The globular part of the pro-segment
docks into the enzyme moiety and shields the S2–S4
substrate binding sites, promoting inhibition. Interest-
ingly, important differences are found in the pro-
segment which allow the identification of the structural
determinants of the diverse activation behaviours of
procarboxypeptidases A1, B and A2, particularly of
the latter. The benzylsuccinic inhibitor is able to diffuse
into the active site of procarboxypeptidase A2 in
the crystals. The structure of the zymogen–inhibitor
complex has been solved at 2.2 Å resolution. The
inhibitor enters the active site through a channel
formed at the interface between the pro-segment and
the enzyme regions and interacts with important ele-
ments of the active site. The derived structural features
explain the intrinsic activity of A1/A2 pro-enzymes for
small substrates.
Keywords: activation/carboxypeptidase A2/inhibition/
pro-enzyme/three-dimensional structure
Introduction
Pancreatic carboxypeptidases are a family of zinc-con-
taining exopeptidases, involved in the digestion process,
which catalyse the hydrolysis of alimentary proteins and
esters from their C-terminus (see Avile´s et al., 1993 and
references therein). They are secreted as zymogens which
are proteolytically activated in the duodenum, producing
the active form. In the process of activation of these
pro-enzymes, a segment of ~94–95 residues is released
(Rinderknecht, 1993). This segment, known as the ‘pro-
segment’ or ‘activation segment’, acts as a clamp of the
active site of the carboxypeptidase, impeding most or all
enzymatic activity. Traditionally, carboxypeptidases were
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classified into A and B forms with regard to their different
substrate specificity: CPA has a preference for aliphatic
and aromatic C-terminal residues, and CPB for basic
C-terminal residues. More recently, two different isoforms,
A1 and A2, were distinguished in the rat (Gardell et al.,
1988; Oppezzo et al., 1994) and in humans (Pascual et al.,
1989; Catasu´s et al., 1995). The A1 isoform, which
corresponds to the previously named ‘A’, shows a prefer-
ence for aliphatic C-terminal residues of peptide substrates,
while the A2 isoform has a clear specificity for bulkier
aromatic C-terminal residues, being the only isoform
which shows specificity towards tryptophan. Human pro-
carboxypeptidase A2 (PCPA2) has been cloned by one of
our laboratories (Catasu´s et al., 1995) and shows an 89%
sequence identity to rat PCPA2, 64% identity to human
PCPA1 and 42% to human PCPB.
It is presently accepted that the peptide hydrolysis
mechanism of pancreatic metallo-carboxypeptidases
follows the water-promoted pathway (Christianson and
Lipscomb, 1989) in which Zn2, active site water, Glu270
and Arg127 play an essential role. These elements, together
with other important active centre residues, such as
Asn144, Arg145 and Tyr248, are found in all active forms
where they seem to play the same, well-characterized role.
The knowledge of the precise and differential role that
other residues play in the several active centre subsites
(S1, S1, S2, S3 and S4) and main specificity subsite
(formally enclosed in S1) proposed for metallo-carboxy-
peptidases is moderate because their variability is greater
and because most of the crystal structures of enzyme and
enzyme–inhibitor complexes have been obtained only for
bovine CPA1 or homologous enzymes and for small
inhibitors (Christianson and Lipscomb, 1989; Kim and
Lipscomb, 1991; Mangani et al., 1992). An exception to
this is the crystal structure of rat CPA2 (Faming et al.,
1991). From the crystal structures of zymogens, such as
porcine PCPA1 (Guasch et al., 1992) and porcine PCPB
(Coll et al., 1991), and of the CPA1–potato carboxypeptid-
ase inhibitor complex (Rees and Lipscomb, 1982), it has
been possible to further delineate such extended active
centre subsites. From the former structures it is also
possible to understand some features of the inhibition
and activation mechanisms of metallo-carboxypeptidase
zymogens. However, significant questions remain to be
answered. Among others, it has been reported that the
A2 zymogens show inhibition properties and activation
mechanisms much more similar to the B than to the A1
forms (Pascual et al., 1989; Oppezzo et al., 1994), in spite
of the fact that the sequences and modelled structures are
more similar in the A1/A2 forms (Catasu´s et al., 1995).
In this work, the three-dimensional structure of a human
carboxypeptidase, CPA2, in its pro-form (PCPA2) is pre-
sented for the first time. This is also the first crystallo-
graphic report on a procarboxypeptidase of the A2 type.
Crystal structure of human procarboxypeptidase A2
Fig. 1. Ribbon diagram of the three-dimensional crystal structure of
recombinant human PCPA2. The globular part of the pro- (activation)
segment covers the active centre and is linked to the enzyme by a
helical connecting segment followed by a loop. Activation with trypsin
occurs between the latter two structures (the primary cleavage site is
indicated with an arrow). Arginine residues at this boundary are
depicted.
Additionally, the crystal structure of this zymogen com-
plexed with the inhibitor L-benzylsuccinic acid (PCPA2–
BZS) has been derived. This inhibitor has been used as a
probe to test the accessibility and functionality of the
preformed active site of the zymogen. BZS acts as a
competitive inhibitor of both peptide and ester hydrolysis,
with Ki  4.510–7 M (Byers and Wolfenden, 1973), and
mimics the product of peptide hydrolysis, since it contains
a moiety analogous to L-Phe and a group which emulates
a peptide (Mangani et al., 1992). A diffusion experiment
was performed over the capillary-mounted crystal after
the collection of the unliganded structure data set. To our
surprise, the analogue is able to enter the active centre
pocket despite the presence of the activation (or inhibition)
domain capping the pocket, promoting a concomitant
movement of Tyr248 as in the fully activated enzyme.
The derived structures clarify significant properties of
metallo-carboxypeptidase zymogens. In addition, they are
of biotechnological interest in providing the structural
basis for the redesign of human carboxypeptidases to
act as optimum pro-drug activators for tumour therapy,
following the recently proposed antibody-directed pro-
drug chemotherapy (Huennekens et al., 1994).
Results and discussion
Human PCPA2 has a globular shape with two clearly
separated moieties: the pro- or activation segment of 96
residues, and the carboxypeptidase A2 moiety with 305
residues (Figure 1). The distance between both moieties
is shifted two residues towards the C-terminus with respect
to previous sequence alignments (Catasu´s et al., 1995),
and to the structure of the A1 and B homologous forms
(Avile´s et al., 1993), as deduced from the analysis of the
conformation and the activation sites carried out in this
work (see below). The numbering of both moieties is
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based on 3-D structure alignments, and an explanation of
the conventions used can be found in the last paragraph
of Materials and methods.
Activation segment of human PCPA2
The activation segment is divided into two different
regions, as described for porcine PCPB (Coll et al., 1991).
These two regions are the large N-terminal globular
domain, which shields the preforming active site of the
enzyme, and a long α-helix, or connecting segment, which
links the globular domain with the enzyme. The connecting
segment is where proteases (mainly trypsin) perform the
activation by cleavage. The globular N-terminal domain
(residues 4A–80A) has an open-sandwich antiparallel-α/
antiparallel-β fold, with two α-helices and four β-strands
which follow the β1α1β2β3α2β4 topology (Figure 1).
When comparing this domain with its equivalent in porcine
PCPB, an insertion of two residues (Leu34B and Gln34C)
occurs and four residues (43A–46A) are absent. This
deletion, which corresponds to a 310 helix in PCPB, was
also observed in porcine PCPA1 (Guasch et al., 1992)
and probably has important consequences for facilitating
the presence of a remnant (intrinsic) activity for small
substrates, as discussed below. The C-terminal connecting
segment comprises residues Val82A to Arg2 (CPA2
numbering) forming the longest α-helix described for pro-
segments of carboxypeptidases at this location (α-helix
3). This helix has five turns and is followed by a short
loop at the border with the CPA2 moiety. At the C-terminal
end of the α3 helix, there are three arginines in a row—
Arg97A, Arg98A and Arg99A—followed by Glu1 and a
fourth arginine residue, Arg2. All are well defined in the
electron density and are solvent-accessible. This unusual
concentration of arginines is the target of the sequential
activation by trypsin (D.Reverter, unpublished results),
which initially cuts at Arg2, the most exposed of the four
(Figure 1). In contrast, the connecting segment of porcine
PCPA1 has only a four-turn helix, followed by a short
loop where only one arginine (Arg99A) is present and
exposed. In porcine PCPB, the equivalent α3 helix is even
shorter, with only two helical turns, and the region linking
to the enzyme is in a loose conformation (see comparison
in Figure 2).
CPA2 moiety of human PCPA2
Human CPA2, the core of the pro-enzyme, maintains the
same fold as its other non-human homologues (Rees et al.,
1983): eight α-helices (α4–α11) and a mixed eight-
stranded β-sheet (β5–β12) forming a globular α/β protein
(Figure 1). In comparison with porcine PCPA1, used to
solve the crystal structure, there are two deletions at
positions 6 and 57 (threonine and serine, in CPA1). The
first deletion is located in the loop which follows the α3
helix-connecting segment, the zone at which the enzyme
moiety starts. It is at the beginning of this loop, which is
longer in porcine PCPA1, where the first proteolytic cut
takes place. Deletion at position 57 is located in the coil
between strands β6 and β7.
As in porcine PCPA1 (Guasch et al., 1992) and bovine
PCPA1 (Gomis-Ru¨th et al., 1995), in human PCPA2 there
is a disulfide bond between Cys138 and Cys161. However,
a second disulfide bond exists in the present structure
linking Cys210 and Cys244. This feature is unique for
I.Garcı´a-Sa´ez et al.
Fig. 2. Comparative diagram showing the C tracings of the pro-segments of porcine PCPA1 (left), human PCPA2 (centre) and porcine PCPB,
followed by the loops linking them with the corresponding enzyme moieties. The pro-segments have a similar topology in the globular part—except
for a 310 helix present only in the B isoform—but have different lengths in the α-helix in the connecting segment. The linking loop (spanning the
boundary between the pro- and enzyme regions in the A1 and B forms, and fully at the enzyme region in A2) also shows a significant difference in
conformation, being longer in PCPB.
PCPA2. There are three disulfide bridges in porcine PCPB
(Coll et al., 1991), but none at residues 210–244. This
link in the present structure affects the position of a loop
region, residues 210–212 being displaced 1.8 Å when
compared with PCPA1 or PCPB. Furthermore, the disulfide
bridge is spatially close to residues involved in the active
site, Ile247 and Tyr248, which are also slightly displaced
and could influence the specificity of the enzyme. More-
over, as previously reported for other pancreatic carboxy-
peptidases, three cis-peptide bonds are located between
residues Ser197–Tyr198, Pro205–Tyr206 and Arg272–
Asp273.
In the preformed active site of PCPA2 the typical
coordination of the Zn2 atom described for carboxy-
peptidases was found. This atom is liganded to a catalytic
water molecule and to the enzyme by His69, His196 and
Glu72, the latter in a bidentate form. The well-structured
arrangement of His196 coordinated with Zn2 forces the
formation of the Ser197–Tyr198 cis-peptide bond between
the two following residues; we should also note that the
other two cis-peptide bonds are very close to residues
involved in the active site which need to be kept in their
appropriate positions.
Residues which form the different active-centre subsites
are substantially conserved if compared with other pancre-
atic metallo-carboxypeptidases. The S1 subsite, which
forms a pocket involved in the anchoring and neutralization
of the C-terminal carboxylate of the substrate, is still
formed by Arg145, Asn144 and Tyr248. The latter caps
this pocket once the benzylsuccinic acid inhibitor is bound
(see below). Subsites S1 (Arg127 and Glu270), which
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contribute to the polarization of the carbonyl of the scissile
peptide bond of the substrate and to the proton exchange,
S2 (Arg71, Ser197, Tyr198, Ser199) and S3 (Phe279),
involved in binding and torsion of peptide substrates, also
remain unchanged. The only difference is at subsite S4,
where Gln122, Arg124 and Lys128 are present in bovine
CPA1 (Catasu´s et al., 1995), while Lys122, Arg 124 and
Lys 128 are found in human PCPA2.
The main putative specificity pocket of the enzyme
moiety was found to be empty in the crystal structure of
PCPA2. This cavity is formed in this enzyme by Asn144,
Ile194, Met203, Ile243, Ile247, Ala250, Gly253, Ser254,
Ile255, Asp256 and Ala268, which are better delineated
in the complex with BZS (see later). Substitutions at
positions 194, 203 and 268 for smaller or more hydro-
phobic residues with respect to the A1 forms are probably
responsible for the higher specificity of CPAs for bulky
aromatic residues.
Interaction of the pro-region with the enzyme: the
inhibition mechanism
The pro-region establishes an extensive interaction with
the enzyme moiety (Table I), burying a surface of 1375 Å2,
of which 760 Å2 correspond to the interaction of the
N-terminal globular domain of the former with the enzyme.
The binding between both regions occludes the S2, S3
and S4 active centre subsites of the enzyme, a fact which
should make the recognition of large peptide substrates
by the enzyme difficult. However, the S1 and S1 subsites
(Asn144, Arg145, Tyr248, Glu270 and Arg127) are not
directly shielded in the pro-enzyme. This could explain the
Crystal structure of human procarboxypeptidase A2
Table I. Interactionsa between the pro-segment and the CPA2 moiety in human pro-CPA2
Globular domain/CPA2 Distance (Å) Connecting segment/CPA2 Distance (Å)
N(Glu5A)--O(Lys122) 3.0 Cγ1(Val82A)...Cδ1(Leu280) 4.0
O(Glu5A)--W2--N(Lys124) 3.0/2.9 Cβ(Leu85A)...Cδ1(Leu280) 3.9
O(Glu5A)--W2--O(Lys124) 3.0/3.5 O(Leu85A)--W64--O (Leu280) 3.4/2.9
Cε1(Phe7A)...Cγ(Met125) 3.7 Cδ1(Leu86A)...Cγ(Arg124) 3.8
Cζ(Phe7A)...Cγ(Met125) 3.7 Oε1(Glu89A)--Nη2(Arg124) 2.9
Oε2(Glu33A)--Nδ2(Asn159) 3.3 Oε2(Glu89A)--Nε(Arg124) 2.8
Oδ1(Asp36A)--Nη2(Arg71) 2.8 Cδ(Glu89A)--Cζ3(Trp73) 3.7
Oδ1(Asp36A)--Nη1(Arg71) 3.4 Oε1(Glu89A)--W65--O(Leu281) 2.8/2.9
Oδ2(Arg36A)--Nη2(Arg71) 3.0 Oε2(Glu92A)--Nη2(Arg284) 3.3
Oδ1(Asp36A)--W55--Oδ2(Asp163) 2.7/2.8 Oε1(Glu92A)--W132--Nε(Ala283) 2.9/3.0
O(Trp38A)--W120--Nη1(Arg71) 3.1/3.1 Oε1(Glu92A)--W100--N(Arg284) 2.8/2.9
Cγ(Trp38A)...Cε2(Phe279)b 3.5 Oε1(Glu92A)--W00--Nε(Arg284) 2.8/2.9
Cζ3(Trp38A)...Cα(Gly278) 4.0 O(Met93A)--W87--O(Tyr12) 2.9/2.9
Nζ(Lys39A)--W256--O(Val246) 2.8/2.7 O(Asn96A)--N(Glu1)e 2.8
N(Ser40A)--W13--O(Tyr248)c 3.3/3.2 Nδ2(Asn96A)--Oε2(Glu1) 2.9
O(Ser40A)--W13--O(Tyr248)c 3.2/3.2 Oδ1(Asn96A)--Nδ2(Asn8) 3.0
Cγ2(Thr42A)...C(Ile247) 3.9 Cγ(Asn96A)--Cβ(Ala11) 3.6
Cγ2(Thr42A)...Cε2(Tyr248)d 3.5 O(Arg97A)--N(Arg2)e 3.5
Cγ2(Thr42A)...Cβ(Tyr248)c 3.8 O(Arg97A)--N(Glu1)e 3.3
Cγ2(Thr47A)...Cε2(Tyr248)d 4.0 Nη2(Arg97A)--W36--O(Tyr12) 2.7/3.5
Nδ1(His53A)--Oη(Tyr198) 2.7 Nε(Arg97A)--W36--O(Tyr12) 2.9
Sδ(Met78A)...O(Gly275) 3.7 O(Arg98A)--N(Glu1)e 3.3
Sδ(Met78A)...C(Gly275) 4.0 O(Arg98A)--N(Arg2)e 3.9
O(Arg99A)--N(Gly4)e 3.1
O(Arg99A)--N(Gly3)e 3.1
O(Met93A)--W87--O(Tyr12) 2.9/2.9
Nδ2(Asn96A)--W87--O(Tyr12) 2.7/2.9
Nε(Arg97A)--W36--O(Tyr12) 2.9/3.5
Nη2(Arg97A)--W36--O(Tyr12) 2.7/3.5
a(...):van der Waal’s contacts 4.0 Å; (--): H-bonds 3.5 Å.
bAromatic–aromatic interaction; only the shortest distance between the two rings is listed.
cIn the benzylsuccinate complexed structure.
dIn the uncomplexed structure.
eIntrahelical H-bond.
small, but clearly detectable, intrinsic hydrolytic activity of
human PCPA2 towards small peptide substrates, which
attains a 0.5–10% level with respect to the active enzyme
according to the nature and size of the substrate
(D.Reverter, unpublished results). These results show that
the active centre is preformed in PCPA2, and that the pro-
region is unable to fully inhibit the enzyme moiety. This
situation is in contrast to porcine PCPB in which no
intrinsic activity towards small peptide substrates is
measurable; the strong inhibition of PCPB is probably
due to the partial shielding of the S1 and S1 subsites
(Coll et al., 1991).
The important consequences of the absence of residues
43A–46A in human PCPA2, in comparison with porcine
PCPB, should be noted. This deletion (or insertion in
PCPB) is located in the loop which connects β2 and β3
strands of the activation segment, just over the active site.
In the PCPA2 case, the loop adopts a straight conformation
and does not physically cap the active site, as occurs in
porcine PCPB where it forms a 310 helix which covers
the active site pocket. PCPB also shows a salt bridge
between Asp41A and Arg145, a bridge which probably
prevents the anchorage of substrates by its C-terminal
carboxyl to the enzyme (to Arg145), and which does not
exist in human PCPA2. The above deletions in human
PCPA2 allow the formation of a clear channel at the
interface between the pro-segment and the enzyme which
make the active site accessible (see Figure 3). This channel
is flanked by Tyr248 in its open position in the unliganded
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PCPA2, pointing out towards the solvent. We shall see
later that in the PCPA2–BZS complex the side chain of
Tyr248 swings into the channel, closing it.
Comparison between the unliganded human
PCPA2 and its complex with benzylsuccinic acid
The three-dimensional structure of the PCPA2–BZS com-
plex, obtained by diffusion in situ of the inhibitor in the
crystal of the unliganded pro-enzyme after data collec-
tion, has been solved at 2.19 Å resolution. The r.m.s.
deviation between unliganded PCPA2 and the PCPA2–
BZS complex has been checked, giving an overall r.m.s.
difference of 0.254 Å for the backbone of the zymogen.
The main differences in the main chains are found in the
loop which connects strands β2 and β3 at the pro-segment,
from residue Pro40A to Pro48A, where Thr42A moves
1.3 Å from its position in the unliganded structure. The
differences are caused by the presence of the inhibitor in
the active site pocket and the concomitant rotation of the
Tyr248 side chain. In its closed or inner position (see
above), this side chain would clash with the Thr42A side
chain in its unliganded position. Also other rearrangements
at the active site and its environment occur to accommodate
the inhibitor, but they mainly affect side chains.
Presumably, BZS diffuses into the active site through the
above-mentioned channel at the surface of the zymogen.
This channel is closed in the PCPA2–BZS complex by
Tyr248 due to a rotation of 165° of its χ1 torsion angle, by
which its hydroxyl group moves 12.7 Å and points
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Fig. 3. Surface representation and electrostatic potential, calculated
with GRASP (Nicholls et al., 1993), of human PCPA2 in the
unliganded form (this work) (A), and porcine PCPB (Coll et al., 1990)
(B). The pro-segment is on top, covering the active centre of the
enzyme moiety. A channel between both regions, making the active
site accessible for small substrates, is present in PCPA2 but not in
PCPB. This channel becomes closed in the inhibitor-complexed
structure of PCPA2 due to a swing movement of Tyr248.
towards one carboxyl group of the inhibitor (Figure 4).
The structure of the complex demonstrates that this
movement does not have steric restrictions even though
it takes place in the zymogen form of the protein. This is
another proof of the intrinsic functionality of the preformed
active centre of PCPA2, in agreement with its residual
activity towards small peptide substrates. It is worth
mentioning that the long-range movement of Tyr248 in
carboxypeptidases (from the up to the down position),
and of its associated loop, has been used as a model
example of the induced fit of enzymes during substrate
6910
binding (Christianson and Lipscomb, 1989). Other import-
ant active site residues, such as Arg127, Arg145 and
Glu270, have also suffered deviations in the PCPA2–BZS
complex in comparison with those in unliganded pro-
enzymes.
It has been demonstrated that bovine CPA1 shows
preference for the L-form in a mixture of L- and D-
benzylsuccinic acid (Byers andWolfenden, 1973; Mangani
et al., 1992). In the present case, a molecule of L-
benzylsuccinic acid diffused selectively into the pre-
formed active site of PCPA2, displacing four molecules
of water, including the catalytic one which was coordinated
with the zinc atom in the unliganded structure. Carboxylic
oxygens O1 and O2, of L-BZS, are coordinated in a
symmetric bidentate form with the Zn2, at 2.5 Å distance.
The inhibitor is also bound to the enzyme by its other
carboxylic oxygens, O3 and O4, which establish hydrogen
bonds with the guanidinium groups of Arg145, Arg127
and Tyr248. Arg127 in PCPA2–BZS also interacts with
O1. The interaction which exists between the Nδ2 atom
of Asn144 and the BZS benzyl ring, at 3.4 Å distance,
should also be noted. This interaction helps to position
the benzyl ring in the hydrophobic pocket.
It has been described for bovine CPA–inhibitor com-
plexes, including transition state analogues, that the co-
ordination of Glu72 with the Zn atom changes from
bidentate in the unliganded structure to monodentate, as
a consequence of the slight movement of the zinc atom
(Christianson and Lipscomb, 1986; Shoham et al., 1988;
Mangani et al., 1992). We do not find such a change in
our structures.
The presence of BZS in the preformed active site of
PCPA2 helps to delineate the specificity pocket. In this
pocket the benzyl group of the inhibitor, which mimics
the side chain of substrates bound at S1, is surrounded
by residues Asn144, Ile194, Met203, Ile243, Ala250,
Gly253, Ser254 and Ala268. Residues Ile247 and Ile255
are also close to BZS. Residue 268 is a threonine or a
serine in bovine or porcine PCPA1. This fact determines,
for human PCPA2, a wider pocket which can accommodate
bulkier residues in comparison with PCPA1. It also has a
stronger hydrophobic character because of this substitution
and the presence of an isoleucine residue at position 194,
which is a serine in PCPA1.
Activation mechanism in human PCPA2
A faster activation by trypsin cleavage for PCPBs than
for PCPA1s (Avile´s et al., 1993; Villegas et al., 1995) has
been described. On the other hand, human and rat PCPA2
show much closer activation rates to PCPB than to PCPA1
(Pascual et al., 1989; Oppezzo et al., 1994). These
differences could be primarily due to a slower degradation
of the pro-segment in PCPA1s as well as to a remaining
inhibitory capability of large fragments of the segment
after cleavage. In contrast to PCPA1, the whole severed
segment and fragments would not be inhibitory in PCPBs
and PCPA2s.
In human PCPA2, the target of activation by trypsin
cleavage is initially the arginyl peptide bond between
Arg2 and Ser3 (enzyme numbering) located at the end of
the well-structured connecting segment, in the C-terminus
of helix α3 (D.Reverter, unpublished results). Subsequent
cleavages occur at Arg99A and Arg97A, at the preceding
Crystal structure of human procarboxypeptidase A2
Fig. 4. Differences in three-dimensional structure of human PCPA2 at its active centre when unliganded (blue) or liganded (pink) with
benzylsuccinic acid (red). Important residues for binding and catalysis are labelled. The major change is detected for the Tyr248 side chain, which
rotates 165° around its χ1 angle, moving its hydroxyl group 12.7 Å, and enters the active site in the complexed structure. The electron density
corresponds to a 2.5 Å resolution Fo–Fc Fourier map, contoured at 2σ, and calculated before adding the inhibitor molecule.
helical turn of the well-structured α3 helix (Figure 1). No
other cleavages take place in the pro-segment. It has also
been shown that the first cleavage is sufficient for the
release of the pro-segment and the full generation of
activity (D.Reverter, unpublished results). Why does this
release take place in spite of the extensive interaction
(Table I) between pro-segment and enzyme? What are the
precise structural determinants of the activation?
In both porcine PCPA1 and PCPB, the first tryptic
cleavage occurs at an arginyl peptide bond located in a
flexible region at the end of the connecting segment, at
the boundary with the enzyme. The first cleavage in
PCPA1 is followed by a trimming of the C-terminus of
the pro-segment by the generated CPA1 and by a second
tryptic cleavage at the peptide bond ArgA74–TyrA75, far
upstream within strand β4 at the globular domain of the
pro-segment. Both types of cleavage are required for full
activation (Vendrell et al., 1990). The first cleavage in
PCPB is followed by a trimming of the C-terminal residue
of the pro-segment by the generated CPB, and by a second
tryptic cleavage at the ArgA83–SerA84 peptide bond, in
the N-terminal part of helix α3. However, in this case,
the first tryptic cleavage is sufficient to generate full
activity (Burgos et al., 1991; Villegas et al., 1995). It has
been proposed (Avile´s et al., 1993) that this differential
behaviour is mainly due to the different degrees of
structuration of the connecting segment of both pro-
enzymes and of the extension and nature of their contacts
with the enzyme moiety. Nevertheless, this hypothesis
does not seem to have a general validity for PCPs in light
of the crystal structure of PCPA2 reported here: the
connecting segment and its long α3 helix in the human
PCPA2 three-dimensional structure show an interactive
6911
surface with the enzyme moiety (692 Å2) more extensive
than the equivalent pieces in porcine PCPA1 and PCPB
(566 Å2 and 539 Å2, respectively). This interaction is
strengthened by two salt bridges in PCPA2, between the
Oε2 of Glu89A and the Nη2 atom of Arg 124, and the Oε2
of Glu92A and the Nη2 atom of Arg 284 (Table I); in
porcine PCPA1 only the salt bridge between GluA89 and
Arg124 is present, and in porcine PCPB both salt bridges
are lacking.
Given that the connecting segment of PCPA2 is the
better structured one within PCPs and the one with stronger
contacts with the enzyme moiety, we should conclude that
the different velocities of the activation process in PCPs
are mainly determined by its complementary piece, that
is by the inhibitory capability of the pro-segment globular
domain when cut from the pro-enzyme. The larger buried
surface between the pro-segment globular domain and the
enzyme moiety in PCPA1 (861 Å2) with respect to PCPA2
(760 Å2) and PCPB (755 Å2) is in agreement with this
interpretation. In particular there are four amino acids,
spatially located very close together, in the β-sheet of the
globular domain of the pro-segment of PCPA1 which
strongly interact with the enzyme moiety (Arg14A–
Thr274, Arg39A--Ser199, Arg47A--Ile244 and Phe50A...
Val246). None of these interactions are present in human
PCPA2. Also, the entire electrostatic energy of interaction
between both pieces, as measured by the GROMOS
program (van Gunsteren et al., 1996) is clearly negative
(attractive) in PCPA1, clearly positive (repelling) in
PCPA2, and nearly null in PCPB. Overall, this could lead
to the easy release of the pro-segment globular domain of
PCPA2 when its connecting segment is cleaved and its
interaction with the enzyme is thus weakened. The above-
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described channel between the two moieties of the pro-
enzyme should also facilitate the penetration of water and
small molecules, and dissociation.
We should also consider the possibility that dynamic
effects and long range conformational effects take place
after the first proteolytic cleavage in PCPs, leading to the
repositioning of the two regions of the pro-segment over
the enzyme. This could impair fitting and eventually lead
to the release of the pro-segment (in PCPA2 and PCPB)
or to its further trimming and final release (in PCPA1).
Further work is required to confirm this hypothesis.
It is worth mentioning that native and redesigned active
forms of pancreatic carboxypeptidases, such as bovine
CPA1 and human CPA1 and CPA2, have been proposed
to be used in cancer therapy following the ADEPT strategy
(Huennekens, 1994; Vitols et al., 1995; Laethem et al.,
1996). According to this approach, an antibody specific
for tumoral tissues is covalently linked to a carboxypeptid-
ase-like enzyme able to remove a C-terminal amino acid
(or analogue) from a pro-drug, such as those based on the
methotrexate molecule, transforming it into the active form
near the tumoral tissue. The derived three-dimensional
structures of recombinant human PCPA2 and the PCPA2–
BZS complex could be very useful in the redesign of
human CPA2 to increase its specificity for these or other
pro-drugs, improving its biomedical applicability.
Materials and methods
Protein puriﬁcation
Human recombinant proCPA2 was secreted extracellularly in a Pichia
pastoris heterologous system and purified by chromatographic
approaches (D.Reverter et al., to be published elsewhere in detail). In
summary, the supernatant from a P.pastoris expression medium was
fractionated by hydrophobic interaction chromatography at atmospheric
pressure, followed by FPLC anion exchange chromatography. The peaks
containing the pro-enzyme were located and characterized by enzymatic
analysis on furyl-acryloyl-L-phenylalanyl-L-phenylalanine (FAPP) and
benzoyl-glycyl-L-phenylalanine (BGP), with or without a previous activ-
ation with trypsin, as previously described (Pascual et al., 1989).
Crystallization
Crystals of unliganded PCPA2 were obtained after mixing 4 μl of fresh
concentrated protein solution with 2 μl of 20% PEG, 0.01 M nickel
chloride and 0.1 M Tris–HCl, pH 8.0 as buffer solution, at 4°C. The
crystals were monoclinic and belonged to space group P21, with unit
cell parameters a  42.20 Å, b  87.07 Å, c  59.02 Å and β 
99.35°. The calculated Vm value is 2.23 Å
3/Dalton with one molecule
per asymmetric unit. The nature of the crystals was checked by PAGE,
confirming the presence of the pro-enzyme without any activation
cleavage. To obtain the complex with benzylsuccinic acid (PCPA2–
BZS), the same crystal used for data collection of the unliganded PCPA2
was diffused with the inhibitor. After the initial native data collection,
the X-ray glass capillary was filled with a solution of 10 mM D,L-
benzylsuccinic acid (Sigma) in a stabilization buffer. The capillary was
closed with wax and the crystal was left to soak in this solution for one
week. After this, the solution was removed from the capillary and the
crystal was directly used for X-ray data collection again. The unit cell
dimensions were minimally affected, being a  42.61 Å, b  87.41 Å,
c  60.27 Å and β  99.27°.
Data collection
For the unliganded structure, a 1.8 Å X-ray data set was collected, at
room temperature, using a 300 mm MarResearch Image Plate Detector
and CuKα radiation from an RU200 Rigaku rotating anode source. For
the PCPA2–BZS complex, a 2.2 Å data set was collected, also at room
temperature, using the same X-ray source and the scanner set in the
180 mm mode. Both data sets were processed with the program DENZO-
SCALEPACK (Otwinowski, 1993). The completeness of the data was
checked with PROTEIN (Steigemann, 1991) (Table II).
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Table II. Data collection statistics
PCPA2a PCPA2–BZSb
Number of measurements 327073 136319
Number of unique reflections 37420 20232
(Fo  2σFo)
Completeness (%) (Fo  2σFo)
overall 94.0 90.9
last shell (resolution range) 87.9 80.5
(1.86–1.8 Å) (2.27–2.2 Å)
I/σ(I)
overall 32.6 16.7
last shell (resolution range) 9.1 8.0
(1.86–1.8 Å) (2.27–2.2 Å)
R merge (%) 4.7 6.1
aProcarboxypeptidase A2.
bProcarboxypeptidase A2–benzylsuccinic acid complex.
Table III. Refinement statistics
PCPA2a PCPA2–BZSb
Resolution range (Å) 8.0–1.8 8.0–2.2
Number of reflections (Fo  2σFo) 37092 19802
Total No. of atoms (excluding hydrogens) 3393 3339
Number of solvent molecules 218 150
Metal ions 1 Zn 1 Zn
R-cryst (%)c 19.8 19.4
R-free (%)d 25.3 27.3
R.m.s. deviation from target values
bond lengths (Å) 0.008 0.008
bond angles (°) 1.6 1.5
aProcarboxypeptidase A2.
bProcarboxypeptidase A2–benzylsuccinic acid complex.
cR-cryst  Σhkl±Fobs|–|Fcalc±/Σhkl|Fobs|, for 90% of the data included in
the refinement.
dR-free, for 10% of the data excluded from the refinement.
Structure determination and reﬁnement
The unliganded human PCPA2 structure was determined by molecular
replacement using the structure of porcine pancreatic PCPA1 (PDB code
1PCA; Guasch et al., 1992) as a starting model, with the AMoRe
program (Navaza, 1994). Diffraction data from 8 Å to 4 Å were used
to calculate the rotation and translation functions. The correlation factor
of the best solution was 55.9% and the R-factor 38.6% after the rigid
body ‘fitting’ routine. Combined rounds of positional refinement using
the X-PLOR program (Bru¨nger, 1992) and model building using the
graphic TURBO program (Rousell and Cambillau, 1991) followed. Ten-
percent randomly selected reflections were set aside for the R-free
calculation. The area which required more model building was the
connecting segment of the activation domain. Omit maps were calculated
excluding several residues in the area, and the α-helix was built according
to the residual electron density. Further refinement cycles followed,
increasing the resolution, adding solvent molecules and including
restrained B-factor refinement. The final R-factor is 19.8%, and R-free
is 25.3% (Table III).
The PCPA2–BZS structure was solved using the coordinates of the
previously determined native PCPA2 as a starting model. Rigid body
refinement was performed with the X-PLOR program using data between
10 Å and 4 Å resolution, giving an R-factor of 27.7%. During the entire
refinement process, 10% of the reflections were set aside for the R-free
calculation. The 3.0 Å Fourier maps, with coefficients 2Fo–Fc and Fo–
Fc, were calculated after a few steps of positional refinement in order
to check whether the benzylsuccinic acid inhibitor had diffused into the
active site of the pro-enzyme, in the crystal. Residual electron density,
close to the atom of Zn, fitted very well with the inhibitor coordinates
in its L-form (which were obtained from the complex structure bovine
CPA1/L-benzylsuccinate; Mangani et al., 1992), and revealed that the
small molecule had reached the active site. Several cycles of positional
refinement with XPLOR and model building with TURBO followed,
increasing the resolution. After the final restrained B-factor refinement
cycle, the R-factor was 19.4% and the R-free of 27.3% (Table III).
Crystal structure of human procarboxypeptidase A2
Both uncomplexed and complexed models had good stereochemistry,
as assessed with PROCHECK (Laskowski et al., 1993). Atomic coordin-
ates and structure factors for both structures have been deposited with
the Brookhaven protein data bank.
The numbering of the pro-segments of procarboxypeptidases is based
on that used in Guasch et al. (1992) where (i) numbering is referenced
to that of PCPB, the first 3-D structure obtained for a procarboxypeptid-
ase, and the number of the amino acid positions are followed by ‘A’ to
distinguish them from the positions in the enzyme moiety; (ii) the first
amino acid in PCPA1 and A2 is in position number 4; (iii) a two-amino
acid insertion after position number 34 in the A forms is numbered 34B
and 34C; (iv) amino acids 43A to 46A of PCPB are absent in PCPA1
and A2. The numbering of bovine CPA1 is kept for the enzyme moiety.
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